Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Fiche publication
Date publication
juin 2009
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno, Pr FUMOLEAU Pierre, Dr LIZARD Sarab
Tous les auteurs :
Boidot R, Vegran F, Soubeyrand MS, Fumoleau P, Coudert B, Lizard-Nacol S
Lien Pubmed
Résumé
In this study, we performed a screening of 266 gene expressions in breast carcinomas and carried out correlations with histological response to either FEC-100 (fluorouracil-epirubicin-cyclophosphamide; n = 16) or Tax-Epi (docetaxel-epirubicin; n = 12) treatment. Gene expression in biopsies obtained before and after one course of chemotherapy was analyzed. Expression of specific genes was significantly changed after one course of chemotherapy, particularly for Tax-Epi treatment. Comparison with histological response for both treatments revealed that only good responders exhibited changes in gene-expression profile. These results agree that expression of different genes changes in response to anthracycline-based neoadjuvant chemotherapy and show, for the first time, that response to docetaxel-based treatment implied also changes in gene-expression profile.
Référence
Cancer Invest. 2009 Jun;27(5):521-8.